Influenza News and Research RSS Feed - Influenza News and Research

Influenza (the flu) is a contagious respiratory illness caused by influenza viruses. It can cause mild to severe illness, and at times can lead to death. The best way to prevent the flu is by getting a flu vaccination each year. Every year in the United States, on average 5% to 20% of the population gets the flu; more than 200,000 people are hospitalized from flu complications, and; about 36,000 people die from flu-related causes. Some people, such as older people, young children, and people with certain health conditions, are at high risk for serious flu complications.
Wistar Institute researchers identify specific mutations responsible for ineffectiveness of flu vaccines

Wistar Institute researchers identify specific mutations responsible for ineffectiveness of flu vaccines

Viruses like influenza have the ability to mutate over time, and given that the flu vaccines administered during the 2014-2015 season were largely ineffective at preventing the spread of the flu, it appears the virus that recently circulated had taken on mutations not accounted for when last year's vaccine was developed. [More]
Larrea Biosciences merged into Gordian Holdings

Larrea Biosciences merged into Gordian Holdings

Larrea Biosciences has been merged into Gordian Holdings, Inc. "Marshalling the Body's best Offense and Defense against Disease, Its own Immune System, through Immunotherapy." Gordian Holdings obtained the rights from OnkologixRx, Inc., for the Markets in China and North America. [More]
BiondVax Pharmaceuticals declares closing of over-allotment option granted to underwriters

BiondVax Pharmaceuticals declares closing of over-allotment option granted to underwriters

​BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced the closing of an additional and partial exercise of the over-allotment option granted to the underwriters. [More]
Generic heart disease drugs show promise in patients affected by Ebola virus

Generic heart disease drugs show promise in patients affected by Ebola virus

Generic medications used frequently in the management of heart disease patients also have the potential to bolster the immune systems of patients with Ebola virus and some other life-threatening illnesses, researchers report this week in mBio, the online open-access journal of the American Society for Microbiology. [More]
New research examines antibiotic choice for treating children with community-acquired pneumonia

New research examines antibiotic choice for treating children with community-acquired pneumonia

New Vanderbilt-led research shows hospitals are doing a better job of using antibiotics less commonly associated with antibiotic resistance to treat children hospitalized with community-acquired pneumonia (CAP). [More]
Analysis of transportation data could help predict spread of flu epidemic across the U.S.

Analysis of transportation data could help predict spread of flu epidemic across the U.S.

To predict how a seasonal influenza epidemic will spread across the United States, one should focus more on the mobility of people than on their geographic proximity, a new study suggests. [More]
Public health experts outline strategies for managing MERS-CoV outbreak

Public health experts outline strategies for managing MERS-CoV outbreak

The ongoing outbreak in the Republic of Korea (South Korea) is an important reminder that the Middle East respiratory virus (MERS-CoV) requires constant vigilance and could spread to other countries including the United States. However, MERS can be brought under control with effective public health strategies, say two Georgetown University public health experts. [More]
FDA accepts BiondVax's IND for Multimeric-001 vaccine

FDA accepts BiondVax's IND for Multimeric-001 vaccine

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced that its Investigational New Drug Application (IND) for its Multimeric-001 vaccine (M-001), has been accepted by the US Food and Drug Administration, and the Company was notified by its regulatory advisors that the 'study may proceed'. [More]
BiondVax invited to present at EDUFULVAC-NIAID workshop on immunoassay standardization for universal flu vaccines

BiondVax invited to present at EDUFULVAC-NIAID workshop on immunoassay standardization for universal flu vaccines

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases,today announced that it has been invited to present in a workshop organized by EDUFULVAC, (EDUcate inFLUenza VACcine) a corresponding European Consortium coordinated by the European Vaccine Initiative (Germany) and NIAID (the National Instituteof Allergy and Infectious Diseases, a National Institute of Health branch) in the United States. [More]
Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Amgen today announced that the Company will discuss the data supporting the Repatha (evolocumab) Biologics License Application (BLA) for the treatment of high cholesterol with the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC). [More]
Infection control experts to convene at IPAC Canada conference

Infection control experts to convene at IPAC Canada conference

Infection control experts from across the country will meet in Victoria from June 14-17 at the Victoria Conference Centre for educational workshops and conference. [More]
St. Michael's Hospital researchers find novel method to combat flu virus

St. Michael's Hospital researchers find novel method to combat flu virus

The flu kills hundreds of thousands of people around the world every year, yet there is essentially only one class of drugs to fight the ever-changing virus. Cases of flu resistant to this class of drugs have already been reported and researchers worry a completely new strain of flu could evolve, leading to a pandemic like the one in 1918 that killed approximately 50 million people. [More]
FDA grants exclusivity to Flublok influenza vaccine for 12 years

FDA grants exclusivity to Flublok influenza vaccine for 12 years

Protein Sciences Corporation announced that in a rare move, the FDA is granting exclusivity to Flublok for a period of 12 years. Flublok is the first vaccine awarded this very important status, demonstrating Flublok as a unique and game changing influenza vaccine. [More]
BiondVax provides update on financial results for first quarter 2015

BiondVax provides update on financial results for first quarter 2015

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced its financial results for the first quarter of 2015 and provided a business update. [More]
Nanopatch Jet Coating drug delivery platform wins 2015 Good Design Award

Nanopatch Jet Coating drug delivery platform wins 2015 Good Design Award

Invetech, a leader in instrument development, custom automation, and contract manufacturing, and Vaxxas, a biotechnology start-up and developer of the Nanopatchâ„¢ needle-free drug delivery technology, have been named winners of the 2015 Good Design Award for development of the Nanopatch Jet Coating Instrument, an advanced technology platform to support needle-free dermal drug delivery research and product development. The award was announced last evening at the Good Design Awards Gala Night held in Sydney, Australia. [More]
Clementia Pharmaceuticals commences multi-center study of patients with fibrodysplasia ossificans progressiva

Clementia Pharmaceuticals commences multi-center study of patients with fibrodysplasia ossificans progressiva

Clementia Pharmaceuticals, Inc. today announced that it has commenced enrollment in the second part (Part B) of its natural history study in patients with fibrodysplasia ossificans progressiva (FOP), a rare, severely disabling congenital myopathy characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) that result in the formation of new, abnormal (heterotopic) bone in muscles, tendons and ligaments. [More]
Researchers create new vaccine development method for H5N1, H7N9 strains of avian influenza

Researchers create new vaccine development method for H5N1, H7N9 strains of avian influenza

A recent study with Kansas State University researchers details vaccine development for two new strains of avian influenza that can be transmitted from poultry to humans. The strains have led to the culling of millions of commercial chickens and turkeys as well as the death of hundreds of people. [More]
Second-generation antibiotic shows promise against common bacterial infections

Second-generation antibiotic shows promise against common bacterial infections

Researchers led by St. Jude Children's Research Hospital scientists have developed a second-generation antibiotic that shows early effectiveness against common bacterial infections that pose a serious health threat to children and adults. [More]
Lakewood-Amedex's novel class of antimicrobials prove effective at killing MDR-TB strains

Lakewood-Amedex's novel class of antimicrobials prove effective at killing MDR-TB strains

Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that a recent series of in vitro studies conducted by Southern Research in Birmingham, Alabama, have demonstrated that its novel class of antimicrobials, named bisphosphocins, have proven effective at killing multidrug-resistant (MDR) strains of Mycobacterium tuberculosis, the bacteria responsible for the chronic lung infection tuberculosis. [More]
Non-coding RNAs in maternal food can pass through placenta to regulate fetal gene expression

Non-coding RNAs in maternal food can pass through placenta to regulate fetal gene expression

In a new study published in the Protein & Cell, Chen-Yu Zhang's group at Nanjing University reports that small non-coding RNAs in maternal food can transfer through placenta to regulate fetal gene expression. [More]
Advertisement
Advertisement